Prevalence, predictors of interval colorectal cancer ID'd

June 8, 2012
Prevalence, predictors of interval colorectal cancer ID'd
A variety of procedural and biologic factors contribute to the development of interval colorectal cancers, seen in 7.2 percent of Medicare beneficiaries, according to a study published in the June 15 issue of Cancer.

(HealthDay) -- A variety of procedural and biologic factors contribute to the development of interval colorectal cancers, seen in 7.2 percent of Medicare beneficiaries, according to a study published in the June 15 issue of Cancer.

Gregory S. Cooper, M.D., of the University Hospitals Case Medical Center in Cleveland, and colleagues identified 57,839 patients aged 69 and older diagnosed with colorectal cancer from the linked Surveillance, Epidemiology, and End Results-Medicare database. The frequency and predictors of colorectal cancer cases that develop after a negative colonoscopy (interval cancer) were assessed.

The researchers found that the overall prevalence of interval cancer was 7.2 percent. Proximal tumor location, increased comorbidity, a previous diagnosis of diverticulosis, and having previously undergone a polypectomy all correlated significantly with interval cancer. At the level of the endoscopist, significant risk factors for interval cancer included lower polypectomy rate, higher volume, and specialty other than gastroenterology.

"A significant proportion of patients developed interval colorectal cancer, particularly in the proximal colon," the authors write. "Contributing factors likely included both procedural and biologic factors, emphasizing the importance of meticulous examination of the ."

Explore further: Physicians who play Mozart while performing colonoscopy may improve adenoma detection rate

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Physicians who play Mozart while performing colonoscopy may improve adenoma detection rate

October 31, 2011
Physicians who listen to Mozart while performing colonoscopy may increase their detection rates of precancerous polyps, according to the results of a new study unveiled today at the American College of Gastroenterology's ...

Thiazolidinediones tied to lower cancer risk in diabetes patients

April 27, 2012
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.

ACP releases new colorectal cancer screening guidance statement

March 5, 2012
The American College of Physicians (ACP) today issued a new guidance statement for colorectal cancer screening. Colorectal cancer is the second leading cause of cancer-related deaths for men and women in the United States. ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.